Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Yutaka Niihara, MD, MPH
Researcher Professor of Medicine
David Geffen School of Medicine at UCLA
1124 West Carson Street C-1, Room 12
Torrance, California, United States
Dr. Niihara has been involved in patient care and research for sickle cell disease for most of his career, and is the principal inventor of the patented L-glutamine therapy for treatment of sickle cell disease in which he co-founded the bio-pharmaceutical company, Emmaus Life Sciences, Inc. It is now in phase III clinical trial involving 32 sites throughout US with FDA Drug Designation and Fast Track Designation. Additionally, his laboratory focuses on regenerative medicine using cell sheet technology. This treatment uses autologous progenitor cell sheets to repair damaged organs such as cornea epithelium and myocardium. Currently, he is the Professor of Medicine at the David Geffen School of Medicine at UCLA. His areas of research are sickle cell disease, cancer & carcinogenesis, blood & blood products & transfusions, biological markers and oncology specialized techniques in research such as red cell enzyme studies and red cell nucleotide analysis.
+myBinderRelated Content
-
Transition Toolkit – Sickle Cell Disease CoalitionWhat is transition? Transition is when ...
-
Healthy red blood cells owe their shape to muscle-like structuresRed blood cells are on a wild ride. As t...
-
University of Illinois HospitalThe Sickle Cell Program at UI Health is ...
-
Dana-Farber/Boston Children’s Cancer and Blood Disorders CenterSpecialists in the Sickle Cell Disease P...
-
‘Every Time It’s A Battle’: In Excruciating Pain, Sickle Cell Patients Are Shunted AsideAmy Mason had toughed it out for hours o...
-
Gene-Edited ‘Supercells’ Make Progress In Fight Against Sickle Cell DiseaseDoctors are reporting the first evidence...
-
Webinar Series: Sickle Cell Science: Path to Progress – Sickle Cell Disease Care in the Emergency Department: ...To commemorate Sickle Cell Awareness Mon...
